BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 19144509)

  • 1. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
    Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
    Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor actions of major component 3'-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation.
    Kimura Y; Sumiyoshi M; Baba K
    Cancer Lett; 2008 Jun; 265(1):84-97. PubMed ID: 18358599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
    Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
    Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
    Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
    Forooghian F; Das B
    Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
    Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
    Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
    Oliver VK; Patton AM; Desai S; Lorang D; Libutti SK; Kohn EC
    J Cell Physiol; 2003 Oct; 197(1):139-48. PubMed ID: 12942550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
    Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.
    Dai J; Peng L; Fan K; Wang H; Wei R; Ji G; Cai J; Lu B; Li B; Zhang D; Kang Y; Tan M; Qian W; Guo Y
    Oncogene; 2009 Sep; 28(38):3412-22. PubMed ID: 19597469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
    Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
    Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
    Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
    Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.